Global Cardiac Arrhythmia Monitoring Devices Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, By Devices (Event Monitoring Devices, Continuous Rhythm Monitoring Devices, Holter Monitoring Devices, Other Devices), By Service Providers (Mobile Cardiac Telemetry Monitoring Service Providers, Independent Diagnostic Testing Facilities/Clinics), By Region, By Company 2021-2031F 2021-2031F

Key Insights	Details
Forecast Period	2025 - 2030
Market Size (2025)	USD 8.82 Billion
CAGR (2026-2031)	7.63%
Fastest Growing Segment	Holter Monitoring Devices
Largest Market	North America
Market Size (2031)	USD 13.71 Billion

Market Overview

The Global Cardiac Arrhythmia Monitoring Devices Market is expected to grow from USD 8.82 Billion in 2025 to USD 13.71 Billion by 2031 at a 7.63% CAGR. Cardiac arrhythmia monitoring devices encompass medical technologies designed to detect, record, and analyze cardiac electrical activity for diagnosing and managing irregular heart rhythms. The market growth is primarily driven by the increasing global prevalence of cardiovascular diseases and associated arrhythmias, alongside an expanding aging population naturally susceptible to such conditions. Escalating healthcare expenditure and continuous technological advancements further propel demand. According to the European Heart Rhythm Association, in 2023, the annual median numbers of pacemakers, implantable cardioverter-defibrillators, and cardiac resynchronization therapy cardioverter-defibrillator implantations in ESC member countries were 739, 195, and 54 per million people, respectively.

Despite this robust growth, a significant challenge impeding market expansion stems from the substantial cost of advanced monitoring devices and the complex reimbursement frameworks prevalent across various healthcare systems. These factors often limit patient access and broad adoption, particularly in developing regions.

Key Market Drivers

Global Rise in Cardiovascular Disease Drives Monitoring Demand
The increasing global prevalence of cardiovascular diseases and cardiac arrhythmias stands as a primary catalyst for the Global Cardiac Arrhythmia Monitoring Devices Market. These conditions necessitate accurate and timely diagnosis, directly elevating the demand for monitoring solutions. For instance, the American Heart Association reported in its 2026 Heart Disease and Stroke Statistics Update, published January 2026, that approximately 48.9% of US adults had some form of cardiovascular disease between 2021 and 2023. This widespread burden of heart conditions, including atrial fibrillation and other rhythm disorders, drives continuous demand for devices such as external loop recorders, mobile cardiac telemetry, and implantable loop recorders, enabling early detection and intervention to prevent more severe cardiac events.

Technological Advances and AI-Enhanced Diagnostics Propel Growth
Concurrently, advancements in cardiac monitoring device technology significantly propel market expansion. Innovations focus on improving device accuracy, miniaturization, user comfort, and data connectivity. According to research funded by the British Heart Foundation and presented at the European Society of Cardiology Congress in Munich in August 2026, an artificial intelligence tool was able to identify up to 81% of patients with heart failure and up to 90% of those with heart valve disease from electrocardiogram results. This technological evolution includes the integration of artificial intelligence for enhanced data analysis, leading to more precise diagnoses and reducing false positives. Furthermore, Medtronic reported in its Q4 fiscal 2026 results, released June 2026, that its Cardiovascular Portfolio revenue increased 10.1% organically, indicating robust growth in the broader cardiac device sector.

Download Free Sample Report

Key Market Challenges

Financial Barriers Limit Access and Adoption
A significant obstacle to the global cardiac arrhythmia monitoring devices market expansion is the substantial cost of advanced monitoring technologies and the intricate reimbursement structures across healthcare systems. These financial barriers directly constrain patient access and broad adoption, particularly in regions with limited healthcare budgets. The high cost of device acquisition, coupled with inconsistent and often inadequate reimbursement, discourages healthcare providers from investing in or offering these state-of-the-art solutions. This leads to a disparity in care, where advanced diagnostics and therapies are often unavailable to a large segment of the population in need.

Policy Variability and Reimbursement Cuts Reduce Viability
Reimbursement complexities further compound this challenge, with policies varying significantly by country and even within regions. According to the American College of Cardiology and Heart Rhythm Society, the 2026 Medicare Physician Fee Schedule finalized a nearly 27% reduction in reimbursement for transcatheter left atrial appendage occlusion procedures. Such reductions directly impact the economic viability for healthcare facilities to offer these services, leading to a projected decline of 6% to 7% in overall facility-based cardiology services reimbursement compared to 2025. These financial disincentives reduce the incentive for providers to utilize advanced cardiac arrhythmia monitoring devices, thereby limiting their market penetration and impeding overall growth.

Key Market Trends

Shift to continuous, real-time wearable cardiac monitoring.
The proliferation of wearable cardiac monitoring devices represents a transformative trend, shifting cardiac rhythm management from episodic clinical encounters to continuous, real-time personal oversight. These portable and user-friendly devices empower individuals to monitor heart health actively, facilitating earlier arrhythmia detection and enabling timely intervention outside traditional settings. This increased accessibility improves diagnostic yield and fosters greater patient engagement. For instance, according to AliveCor, Inc., in August 2026, a study published in JACC Advances reported that 39 arrhythmia episodes (11.1%) were captured exclusively by the KardiaMobile 6L device, missed by conventional monitoring options. This diagnostic advantage underscores wearables' growing significance in comprehensive cardiac care.

Medicare expansion and higher reimbursement drive adoption of remote monitoring.
Concurrently, the expansion of remote patient monitoring and telehealth services is fundamentally reshaping cardiac arrhythmia care by extending clinical oversight into patients' homes. This trend mitigates the need for frequent in-person hospital visits, making ongoing management more convenient and accessible. By enabling healthcare providers to analyze cardiac data remotely, these services support proactive care adjustments and reduce acute care facility burden. The financial viability is also strengthening through supportive reimbursement. According to RhythmScience, in February 2026, Medicare coverage for remote cardiac monitoring expanded significantly, with the Centers for Medicare & Medicaid Services updating the total Relative Value Unit for technical component CPT code 93296 from 0.60 to 0.95, resulting in an approximate 60% payment increase. This incentivizes broader integration into standard cardiology practice.

Segmental Insights

Drivers of Holter Monitoring Growth
Holter Monitoring Devices represent the fastest-growing segment within the Global Cardiac Arrhythmia Monitoring Devices Market, driven by several interconnected factors. The escalating global prevalence of cardiovascular diseases, particularly atrial fibrillation, necessitates prolonged cardiac observation to accurately detect intermittent arrhythmias often missed by shorter diagnostic methods. This rising demand for continuous and ambulatory monitoring is further amplified by a broader shift towards remote patient management and home healthcare settings. Moreover, ongoing technological advancements, including the development of more discreet wireless and patch-based devices, significantly enhance patient comfort and compliance, while improved data analysis capabilities, supported by clinical guidelines from bodies like the American Heart Association, foster greater diagnostic accuracy and clinician confidence.

Regional Insights

North America Leads the Cardiac Arrhythmia Monitoring Market Driven by Disease Burden, Regulatory Environment, and Industry Strength
North America leads the global Cardiac Arrhythmia Monitoring Devices Market, driven by a confluence of specific and impactful factors. The region experiences a significant burden of cardiovascular diseases, particularly atrial fibrillation, which necessitates continuous and advanced monitoring solutions. This demand is met by a highly developed healthcare infrastructure and a proactive regulatory environment, including the U.S. Food and Drug Administration's efficient approval pathways, which fosters the rapid introduction and adoption of innovative devices. Furthermore, favorable reimbursement policies and the robust presence of leading medical device manufacturers contribute substantially to North America's prominent market position.

Recent Developments

• In November 2025, Future Cardia, a medical device company focused on implantable cardiac monitors, and Artella Solutions Inc., a provider of remote cardiac monitoring software and clinical services, announced an expanded strategic collaboration. This partnership centered on integrating Artella's Active State Monitoring SaaS platform with Future Cardia's investigational implantable cardiac devices. The collaboration was established to explore improved data integration and clinical workflow capabilities by combining implantable and external monitoring technologies. This initiative aims to advance the analysis of long-term electrocardiogram data for rhythm assessment, enhancing the global cardiac arrhythmia monitoring devices market.
• In June 2024, AliveCor achieved FDA clearance for its Kardia 12L ECG System, a development that was subsequently highlighted in December 2024 and January 2025 news. This system marked a significant new product launch as the world's first AI-powered handheld 12-lead ECG device with a unique single-cable design. Developed for healthcare professionals, the portable device utilizes KAI 12L AI technology to facilitate the rapid and accurate detection of 35 cardiac determinations, including various arrhythmias and potential heart attacks. The innovation aims to enhance access to comprehensive electrocardiogram data within diverse clinical environments.
• In May 2024, Medtronic announced the integration of new artificial intelligence capabilities into its Reveal LINQ insertable cardiac monitors. This product enhancement, part of the AccuRhythm AI platform, was specifically designed to reduce false alerts for atrial fibrillation and pause episodes, benefiting users in the United States, Australia, and New Zealand. Medtronic projected that these advanced AI algorithms could decrease false alerts by up to 85%. This breakthrough research in cardiac monitoring technology aims to improve efficiency for clinicians by saving considerable time in data review, thereby enhancing the overall management of cardiac arrhythmias.
• In April 2024, BIOTRONIK introduced its new BIOMONITOR IV Insertable Cardiac Monitor, which received CE approval and saw its first European implant. This device incorporates artificial intelligence (AI) for significant false positive reduction, particularly in detecting atrial fibrillation, bradycardia, tachycardia, and pause events. The BIOMONITOR IV is designed to differentiate between premature ventricular and atrial contractions, a capability unique in the market, providing enhanced signal quality for reliable remote patient management. This breakthrough research and new product launch aim to optimize clinical workflows by reducing the time clinicians spend reviewing false detections.

Key Market Players

• ACSDiagnostics
• AliveCor Inc.
• Abbott Laboratories
• Biotronik
• GE Healthcare
• iRhythm Technologies Inc.
• Medi-Lynx
• Medtronic PLC
• Koninklijke Philips NV
• Welch Allyn

By Devices	By Service Providers	By Region
Event Monitoring Devices Continuous Rhythm Monitoring Devices Holter Monitoring Devices Other Devices	Mobile Cardiac Telemetry Monitoring Service Providers Independent Diagnostic Testing Facilities/Clinics	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cardiac Arrhythmia Monitoring Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cardiac Arrhythmia Monitoring Devices Market, By Devices:

• Event Monitoring Devices
• Continuous Rhythm Monitoring Devices
• Holter Monitoring Devices
• Other Devices

• Cardiac Arrhythmia Monitoring Devices Market, By Service Providers:

• Mobile Cardiac Telemetry Monitoring Service Providers
• Independent Diagnostic Testing Facilities/Clinics

• Cardiac Arrhythmia Monitoring Devices Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE